促红细胞生成素在治疗新生儿缺氧缺血性脑损伤中的研究

摘要

Neonatal hypoxic-ischemic brain damage(HIBD)is often associated with high mor-tality and serious disorders such as cerebral palsy and mental retardation.It has caused the atten-tion of many researchers due to its enormous influences on economics,mentality and harmony of families.However,the pathogenesis and effective treatment of HIBD still need further investiga-tion.Erythropoietin (EPO),a promising clinical drug,is not widely used in the treatment of HIBD.This paper reviews the pathogenesis of HIBD and current status and prospect of EPO for HIBD.%新生儿缺血缺氧性脑损伤(hypoxic-ischemic brain damage,HIBD)常伴随着高死亡率和严重的功能障碍如儿童脑瘫、智力低下等,对许多家庭造成极大的经济损失及精神损伤,破坏家庭的和谐,早已引发广大研究者的关注及重视.但就目前研究来看,其发病机制还可进一步阐述及寻找新的有效治疗方法.促红细胞生成素(erythro-poietin,EPO)是临床应用比较有前景的治疗药物,目前并未被广泛用于新生儿HIBD治疗.本综述将结合近年来国内外研究现状,从新生儿HIBD的发病机制等探讨EPO治疗新生儿HIBD的现状及前景.